The Phase III RATIFY study (NCT00651261) investigated daunorubicin, cytarabine and the FLT3 inhibitor midostaurin for the treatment of newly diagnosed acute myeloid leukemia (AML). Here, Richard Stone, MD, of the Dana-Farber Cancer Institute, Boston, MA, discusses the questions remaining from this trial, speaking from the International Symposium on Acute Leukemias (ISAL) 2019, held in Munich, Germany.